

# Raymond Farkouh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11548721/publications.pdf>

Version: 2024-02-01

10  
papers

187  
citations

1040056

9  
h-index

1281871

11  
g-index

11  
all docs

11  
docs citations

11  
times ranked

144  
citing authors

#	ARTICLE	IF	CITATIONS
1	Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States. <i>Vaccine</i> , 2022, 40, 4700-4708.	3.8	20
2	Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children. <i>Emerging Infectious Diseases</i> , 2021, 27, 1627-1636.	4.3	24
3	Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis. <i>Infectious Diseases and Therapy</i> , 2020, 9, 305-324.	4.0	14
4	Comment on Gomez et. al. "Response to article by Wasserman et. al. (2018) "Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico" Human Vaccines and Immunotherapeutics, 2019, 15, 572-574.	3.3	1
5	Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 560-569.	3.3	19
6	Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria. <i>Infectious Diseases and Therapy</i> , 2019, 8, 63-74.	4.0	11
7	Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine. <i>Expert Review of Vaccines</i> , 2018, 17, 71-78.	4.4	21
8	Response to McGirr et al.'s Comment on "Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada" <i>Infectious Diseases and Therapy</i> , 2018, 7, 539-543.	4.0	3
9	Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada. <i>Infectious Diseases and Therapy</i> , 2018, 7, 353-371.	4.0	29
10	Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China. <i>PLoS ONE</i> , 2018, 13, e0201245.	2.5	18